Understanding Your Radical Cystectomy Pathology Report

by Jason Wasserman MD PhD FRCPC
March 19, 2026

A radical cystectomy is the surgical removal of the entire bladder and the surrounding tissues and lymph nodes. It is the standard treatment for muscle-invasive bladder cancer and for certain cases of high-risk non-muscle-invasive bladder cancer that have not responded to other treatments. After the operation, the removed tissue is sent to a pathology laboratory where a pathologist examines it carefully and writes a detailed report. This report provides the most complete and definitive assessment of the cancer — its type, depth of invasion, the status of all surgical margins, how many lymph nodes were involved, and whether any additional organs contained cancer.

The radical cystectomy pathology report is one of the most information-dense reports a patient will receive. This article explains what the surgery involves, what the laboratory examines, and what each part of your report means.

What is a radical cystectomy?

A radical cystectomy removes the bladder along with several other structures that are removed at the same time to ensure all local cancer is excised and to provide accurate staging information.

In men, the standard radical cystectomy includes removal of the bladder, the prostate gland, the seminal vesicles, and the proximal urethra (the portion of the urethra attached to the bladder). In women, the standard operation includes removal of the bladder, the uterus, the ovaries, the fallopian tubes, and the anterior wall of the vagina. In both sexes, a bilateral pelvic lymph node dissection is performed at the same time — the lymph nodes in the pelvis along the major blood vessels are removed and sent separately to the pathologist.

Because the bladder stores urine, its removal requires the surgeon to create a new way for urine to leave the body. This is called a urinary diversion. The most common types are an ileal conduit (a short segment of small intestine that connects the ureters to an opening in the abdominal wall called a stoma) and a neobladder (an internal pouch made from intestine that connects to the urethra and allows urination in the normal way). The type of diversion does not affect the pathology report.

Why is a radical cystectomy done?

The most common reason for radical cystectomy is muscle-invasive bladder cancer — cancer that has grown into the muscularis propria (the thick muscular wall of the bladder) and cannot be cured by endoscopic procedures alone. The main indications include:

Muscle-invasive urothelial carcinoma (pT2 or higher). Confirmed on a prior TURBT (transurethral resection of bladder tumour), this is the most common reason for radical cystectomy.
High-risk non-muscle-invasive bladder cancer that has failed intravesical therapy. Some patients with high-grade non-invasive disease, carcinoma in situ (CIS), or recurrent high-grade tumours do not respond adequately to BCG therapy and are offered cystectomy to prevent progression to muscle-invasive disease.
Certain variant histologies. Some aggressive microscopic subtypes of urothelial carcinoma — such as micropapillary, plasmacytoid, or sarcomatoid variants — carry a high risk of progression and may prompt earlier cystectomy even at a lower clinical stage.

Many patients receive neoadjuvant chemotherapy — chemotherapy given before surgery — to shrink the tumour and reduce the risk of the cancer returning after surgery. The pathology report will reflect the status of the tumour at the time of surgery, after any pre-operative treatment.

What does the pathology laboratory do with the radical cystectomy specimen?

The radical cystectomy specimen is large and complex and requires careful examination. Once it arrives in the laboratory, the pathologist begins with a thorough gross examination — inspecting the entire specimen with the naked eye before any tissue is processed.

Gross examination

The gross description records the size and weight of the bladder, the appearance of its outer surface, and the findings upon opening the bladder. The pathologist notes the location, size, and appearance of any visible tumours — whether they are papillary (frond-like projections into the bladder cavity), flat, ulcerated, or solid. The thickness of the bladder wall, the presence of any areas of thickening or induration, and the condition of the overlying fat are all documented. The prostate, seminal vesicles (in men), or uterus and adnexa (in women) are examined separately.

Tissue sampling and microscopic examination

The pathologist takes sections from the tumour at its deepest point of invasion, from all surgical margins, from any additional mucosal abnormalities seen on gross examination, and from the separately submitted lymph nodes. All tissue is processed, embedded in paraffin wax, cut into very thin sections, stained with hematoxylin and eosin, and examined under the microscope. Special stains or immunohistochemistry may be applied if needed to clarify the tumour type or identify variant histology.

Because a radical cystectomy specimen can generate a very large number of tissue blocks, it is common for the final pathology report to take longer than a standard biopsy, often five to seven business days or longer if additional stains are needed.

What does the radical cystectomy pathology report contain?

Radical cystectomy reports are structured to capture all the information needed for definitive staging and treatment planning. The following sections explain what each component means.

Tumour type

The report begins by identifying the type of cancer present. The large majority of bladder cancers are urothelial carcinoma (also called transitional cell carcinoma), arising from the urothelial cells that line the bladder. Less common types include squamous cell carcinoma, adenocarcinoma, and small cell carcinoma. The tumour type influences prognosis and determines whether additional or alternative treatments may be appropriate.

Tumour grade

For urothelial carcinomas, the pathologist assigns a grade based on the appearance of the cancer cells under the microscope. The current grading system uses two categories:

Low grade. Cells are relatively similar to normal urothelial cells and are arranged in an orderly way. Low-grade tumours grow slowly and are less likely to spread.
High grade. Cells look very different from normal urothelial cells and show marked pleomorphism (variation in size and shape). Virtually all muscle-invasive urothelial carcinomas are high-grade.

Variant histology

Some urothelial carcinomas contain areas that look different from standard urothelial cancer under the microscope. These are called histological variants and are important to report because some are more aggressive than typical urothelial carcinoma and may influence treatment decisions. Variants that may appear in the report include squamous differentiation, glandular differentiation, micropapillary variant, plasmacytoid variant, sarcomatoid variant, and nested variant, among others. Your urologist and oncologist will take any variant histology into account when planning further treatment.

Tumour location and size

The report describes where in the bladder the tumour was located — the posterior wall, anterior wall, lateral walls, dome, trigone (the triangular region at the base of the bladder near the ureteral openings), or bladder neck. Tumour size is measured in centimetres. Both location and size contribute to the clinical picture, though the pT stage (described below) is more directly relevant to treatment and prognosis than size alone.

Concomitant carcinoma in situ (CIS)

The pathologist will note whether carcinoma in situ is present anywhere in the bladder, either adjacent to the invasive tumour or at a separate location. CIS is a flat, high-grade non-invasive tumour that can affect large areas of the bladder lining and may also involve the ureters, urethra, or prostatic ducts. Its presence alongside invasive carcinoma is associated with a higher risk of recurrence and may affect the pathological stage if it involves specific margins.

Pathological stage (pTNM)

The pathological stage is one of the most important sections of the report. It summarises how deeply the cancer has grown, whether any lymph nodes contain cancer, and whether there is evidence of distant spread. The staging system used is the internationally standardised pTNM system.

Tumour stage (pT)

The pT stage describes how deeply the tumour has invaded the bladder wall and surrounding structures. This is the definitive assessment, replacing the clinical stage assigned based on imaging and TURBT findings.

pT0 — No residual tumour. No cancer is found in the cystectomy specimen. This occurs when the tumour has been destroyed by neoadjuvant chemotherapy or was entirely removed by prior TURBT. A pT0 result after neoadjuvant chemotherapy is associated with an excellent prognosis.
pTis — Carcinoma in situ only. Only flat high-grade non-invasive cancer is present, with no invasive component identified.
pTa — Non-invasive papillary carcinoma. The tumour is a papillary (frond-like) growth confined to the urothelium with no invasion of the underlying tissue. This stage is uncommon in a cystectomy specimen, as pTa disease is usually managed with TURBT.
pT1 — Invasion of the lamina propria. Cancer cells have grown through the urothelium and into the lamina propria, the connective tissue layer lying immediately beneath the urothelium. The cancer has not yet reached the muscular wall.
pT2 — Invasion of the muscularis propria. Cancer has grown into the thick muscular wall of the bladder. pT2a indicates invasion of the inner half of the muscle; pT2b indicates invasion of the outer half. This is the defining feature of muscle-invasive bladder cancer. When the pathology report confirms pT2 disease in the cystectomy specimen — especially if this is downstaged from what was seen on TURBT — it is relevant to prognosis.
pT3 — Invasion of the perivesical fat. Cancer has grown through the full thickness of the bladder wall and into the fatty tissue surrounding the bladder. pT3a is microscopic perivesical fat invasion (visible only under the microscope); pT3b is macroscopic perivesical fat invasion (visible to the naked eye during gross examination). pT3 disease carries a significantly higher risk of lymph node involvement and systemic spread than pT2 disease.
pT4 — Invasion of adjacent structures. Cancer has spread beyond the bladder into neighbouring structures. pT4a refers to invasion of the prostate stroma (the fibromuscular tissue of the prostate, not just the prostatic ducts), uterus, or vagina. pT4b refers to invasion of the pelvic wall or abdominal wall. pT4 disease is locally advanced and is associated with a high risk of systemic spread.

Nodal stage (pN)

The pN stage reflects the findings in the lymph nodes removed during the pelvic lymph node dissection. Both the number of lymph nodes examined and the number that contain cancer are reported.

pN0. No cancer cells found in any of the examined lymph nodes. This is the most favorable lymph node result.
pN1. Cancer cells are found in a single lymph node in the true pelvis (obturator, internal iliac, external iliac, or presacral nodes).
pN2. Cancer cells were found in multiple lymph nodes in the true pelvis.
pN3. Cancer cells are found in the common iliac lymph nodes, which lie at the boundary between the pelvis and the abdomen.
pNX. No lymph nodes were submitted or found for examination.

The total number of lymph nodes examined is an important quality indicator for the surgery. A more extensive lymph node dissection removes more nodes, which improves staging accuracy and may also have therapeutic benefit. Most guideline-recommended dissections yield 10-16 nodes, and many experienced centres examine considerably more.

The report will also note whether extranodal extension (ENE) is present — meaning that cancer has broken through the outer capsule of a lymph node and spread into the surrounding fat. Extranodal extension in bladder cancer lymph node metastases is associated with a worse prognosis and may influence decisions about adjuvant treatment.

Surgical margins

One of the most important aspects of the radical cystectomy report is the assessment of the surgical margins — the edges of the tissue that the surgeon cut through during the operation. A positive margin means that cancer cells are present at the very edge of the removed specimen, indicating that some cancer may have been left behind in the body. A negative margin means there is a clear zone of normal tissue between the cancer and the cut edge.

The radical cystectomy report assesses several specific margins:

Ureteral margins. The cut ends of the left and right ureters (the tubes that carry urine from the kidneys to the bladder) are examined separately. If cancer — either invasive carcinoma or carcinoma in situ — is present at the ureteral margin, there is a risk that cancer remains in the upper urinary tract, which may require additional surveillance or treatment. Ureteral margins are typically submitted as small donuts of tissue by the surgeon at the time of the operation for intraoperative frozen section assessment.
Urethral margin. The cut end of the urethra, where it was divided from the bladder neck, is assessed. A positive urethral margin — particularly if cancer is present in the urethra itself — increases the risk that cancer remains in the remaining urethra. This is particularly relevant for patients who have had a neobladder constructed, as cancer in the retained urethra would be a significant concern.
Soft tissue (radial/perivesical) margin. The outer surface of the bladder specimen is assessed to determine how close the invasive tumour approaches the surgically cut outer edge. A positive soft tissue margin means that cancer cells are found at the outermost cut surface of the specimen, indicating that the surgeon was unable to achieve a clear plane around all of the cancer. A positive soft tissue margin is an independent risk factor for local recurrence and reduced survival, and typically leads to discussion of additional treatment such as radiation therapy.
Prostatic urethral margin (in men). In male patients, the report will assess whether cancer involves the prostatic urethra or the stroma of the prostate. Urothelial carcinoma extending into the prostatic stroma (not just the prostatic ducts) is classified as pT4a disease, as noted above.

Findings in the concomitant specimens

Because the radical cystectomy removes additional organs alongside the bladder, the pathology report will describe the findings in each of these structures.

In male patients: prostate and seminal vesicles

The prostate gland removed with the cystectomy specimen is examined both for urothelial cancer involvement and for any incidental findings of prostate cancer. The report will note:

Whether the prostatic ducts or prostatic stroma are involved by urothelial carcinoma or carcinoma in situ.
Whether an incidental prostate adenocarcinoma is present, incidental prostate cancer is found in a significant proportion of radical cystectomy specimens — estimates range from 20 to 50 percent depending on the series — because both diseases share similar risk factors and age distribution. The significance of any incidental prostate cancer found depends on its grade (Gleason score and Grade Group), its extent, and whether it has spread beyond the prostate. Your urologist will discuss any prostate cancer findings with you separately.
Whether the seminal vesicles are involved by urothelial carcinoma (seminal vesicle invasion by bladder cancer is classified as pT4a disease).

In female patients: uterus, ovaries, fallopian tubes, and vaginal cuff

The uterus, ovaries, fallopian tubes, and anterior vaginal wall removed with the cystectomy are examined for involvement by urothelial carcinoma and for any incidental findings. Incidental findings in these organs, such as endometrial polyps, ovarian cysts, or leiomyomas (fibroids), are relatively common and will be noted in the report. If any of these structures is involved by urothelial carcinoma, the extent and nature of involvement will be described.

Lymphovascular invasion

Lymphovascular invasion means that cancer cells have been found inside blood vessels or lymphatic channels within the bladder tissue. Its presence indicates that cancer cells have found a potential route to travel to lymph nodes or other organs and is considered an adverse prognostic feature, particularly in patients with pT2 disease. Lymphovascular invasion in a cystectomy specimen is associated with a higher risk of lymph node metastasis and systemic recurrence.

Pathologic complete response after neoadjuvant chemotherapy

Many patients with muscle-invasive bladder cancer receive cisplatin-based chemotherapy before surgery — this is called neoadjuvant chemotherapy. Its purpose is to shrink the tumour before the operation and to eliminate any microscopic cancer cells that may have already spread beyond the bladder.

When no residual invasive carcinoma is found in the cystectomy specimen following neoadjuvant chemotherapy, this is called a pathologic complete response (pCR) and is reported as pT0N0. A pathologic complete response after neoadjuvant chemotherapy is one of the strongest favorable prognostic indicators in bladder cancer — patients who achieve pT0 after neoadjuvant treatment have significantly better long-term outcomes than those with residual invasive tumour. Even a reduction in stage from T3 at TURBT to pT2 at cystectomy (downstaging) is associated with improved prognosis compared to no change in stage.

Your oncologist will discuss the implications of the pathological response to neoadjuvant chemotherapy for any further treatment decisions, including adjuvant (post-operative) systemic therapy.

What happens after the radical cystectomy report?

Once your urologist and oncologist have reviewed the complete pathology report, they will discuss the findings with you. The pathological stage established by the cystectomy specimen is the most accurate measure of how far the cancer has progressed and is the primary guide for decisions about further treatment.

For patients with pT0 or pT2N0 disease and negative margins, close surveillance with imaging and urine studies is standard, and many cases do not require immediate further systemic treatment. For patients with pT3 or pT4 disease, positive lymph nodes, or positive margins, the risk of recurrence is substantially higher, and adjuvant treatment — such as immunotherapy with a checkpoint inhibitor or, in some centres, adjuvant chemotherapy — is often discussed. Your oncologist will review the current evidence and your individual circumstances when making these recommendations.

Follow-up after radical cystectomy includes regular imaging, urine cytology, and assessment of the upper urinary tract (kidneys and ureters) to monitor for recurrence. The schedule and investigations will be tailored to your pathological stage and overall risk profile.

Questions to ask your doctor

What is the final pathological stage (pT and pN) of my cancer?
What type of cancer was found, and was any variant histology identified?
Were all surgical margins negative?
If I received neoadjuvant chemotherapy, did I achieve a pathologic complete response?
How many lymph nodes were examined, and how many contained cancer?
Was extranodal extension present in any lymph nodes?
Was lymphovascular invasion seen in the bladder specimen?
Was carcinoma in situ present elsewhere in the bladder, ureters, or urethra?
In male patients: Was any prostate cancer found, and if so, how significant is it?
Based on the pathology, do I need further treatment such as immunotherapy or radiation?
What follow-up schedule do you recommend, and what tests will be done?
What signs of recurrence should I watch for?